Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.

  2. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by

  3. Drug

    Etafedrine

    go.drugbank.com/drugs/DB11587
    Approved

    Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568]. … It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6].

  4. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    unmet medical need based on a surrogate endpoint. … [L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.

  5. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in

  6. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  7. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … [L56116, A275467] Marnetegragene autotemcel, also known as marne-cel, is an autologous hematopoietic stem cell-based gene therapy created from the patient's own hematopoietic stem cells.

    Synonyms: Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 gene
  8. Drug

    Technetium Tc-99m sestamibi

    go.drugbank.com/drugs/DB09161
    ApprovedInvestigational

    Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. … detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  10. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].